Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Study Evaluates Population-Wide Testing and Early Treatment for HIV Prevention

Published: Monday, September 30, 2013
Last Updated: Monday, September 30, 2013
Bookmark and Share
A study in South Africa and Zambia will assess whether house-to-house voluntary HIV testing and prompt treatment of HIV infection can substantially reduce the number of new HIV infections across communities.

The trial, Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART), or HPTN 071, is sponsored and co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial is funded primarily by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), administered by the Office of the Global AIDS Coordinator.

The PopART study will build on the results of the landmark, NIAID-funded HPTN 052 trial, which found that HIV-infected individuals who start treatment early, when their immune systems are relatively healthy, dramatically reduce the risk of transmitting the virus to their heterosexual partners.

"Through this new study, we aim to learn whether the treatment of HIV-infected individuals as a form of HIV prevention, an approach previously tested in roughly 1,800 heterosexual couples where one partner was infected, will be just as effective when implemented across an entire adult population," said NIAID Director Anthony S. Fauci, M.D. "The study also will tell us whether this method of delivering population-wide HIV treatment as prevention is feasible and cost-effective."

The trial is being conducted in South Africa and Zambia because the HIV prevalence in those countries is among the highest in the world. An estimated 12.5 percent of adults in Zambia and 17.3 percent of adults in South Africa are infected.

Leading the study are Richard Hayes, D.Sc., professor of epidemiology and international health at the London School of Hygiene and Tropical Medicine, and Sarah J. Fidler, Ph.D., reader in the Department of Medicine at Imperial College London.

"Mathematical models indicate that if a high proportion of a population can be tested for HIV, and those found to be infected are offered treatment right away, then the rate of new HIV infections could decrease substantially over time," said Dr. Hayes. "The PopART study is assessing whether this approach works and whether the benefits outweigh the costs -- information that could help guide public health policy."

The PopART study investigators have designed an HIV prevention package that includes

 -- Door-to-door, voluntary HIV testing offered at annual intervals

 -- Linkage of those who test positive for the virus to care at local health centers

 -- Promotion of voluntary medical circumcision to men who are not HIV-infected

 -- Promotion of steps to prevent mother-to-child HIV transmission

 -- Referral of individuals with other sexually transmitted infections to treatment

 -- Provision of condoms

The PopART trial will involve 21 communities in South Africa and Zambia with a total population of 1.2 million.  The study team has randomly assigned each community to one of three groups. One group of communities will receive the HIV prevention package along with the opportunity for HIV-infected individuals to begin treatment as soon as they test positive for the virus. The second group will receive the same HIV prevention package, and infected individuals will be offered treatment at the stage of infection recommended by their country's HIV treatment guidelines. The third group will serve as a control and will receive existing HIV prevention and testing services along with HIV care and treatment according to current national guidelines for their country.

The study team will measure the impact of the two HIV prevention packages by determining the number of new HIV infections among a representative sample of 52,500 adults drawn from the 21 study communities and followed for three years. The study is expected to end in 2019.

The study research is being conducted by investigators at the NIH-funded HIV Prevention Trials Network (HPTN), the London School of Hygiene & Tropical Medicine, Imperial College London, the Zambia AIDS-Related Tuberculosis Project and the Desmond Tutu TB Centre of South Africa. PEPFAR partners will provide HIV care and treatment to the study communities under the direction of the U.S. Agency for International Development and the U.S. Centers for Disease Control and Prevention.

In addition to PEPFAR and NIAID, study funders include the International Initiative for Impact Evaluation with support from the Bill & Melinda Gates Foundation, as well as the National Institute on Drug Abuse and the National Institute of Mental Health, both part of NIH.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Friday, July 31, 2015
Vital Protein in Healthy Fertilization Process Identified
Researchers at the National Institutes of Health have discovered a protein that plays a vital role in healthy egg-sperm union in mice.
Monday, July 27, 2015
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Saturday, July 25, 2015
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
Tuesday, July 21, 2015
NIH Joins Public-Private Partnership to Fund Research on Autism Biomarkers
Biomarkers Consortium project to improve tools for measuring and treating social impairment in children with autism.
Tuesday, July 21, 2015
NIH Study Identifies Gene Variant Linked to Compulsive Drinking
Mice carrying the Met68BDNF gene variant would consume excessive amounts of alcohol.
Tuesday, July 21, 2015
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Tuesday, July 21, 2015
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Tuesday, July 21, 2015
Futuristic Brain Probe Allows for Wireless Control of Neurons
NIH-funded scientists developed an ultra-thin, minimally invasive device for controlling brain cells with drugs and light.
Saturday, July 18, 2015
House Votes in Favor of Bill Boosting NIH Funding
The US House of Representatives today overwhelmingly voted in favor of a bill that would increase funding to the NIH by about $10 billion, help speed the development of new drugs, and advance precision medicine initiatives.
Monday, July 13, 2015
NIH-funded Vaccine for West Nile Virus Enters Human Clinical Trials
Enrollment is expected to be completed by December 2015.
Tuesday, July 07, 2015
In Blinding Eye Disease, Trash-Collecting Cells Go Awry, Accelerate Damage
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Friday, July 03, 2015
Boys More Likely to Have Antipsychotics Prescribed, Regardless of Age
NIH-funded study is the first look at antipsychotic prescriptions patterns in the U.S.
Thursday, July 02, 2015
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Thursday, July 02, 2015
New Medication for Alcohol Use Disorder
NIH begins clinical trial investigating a potential treatment for alcohol use disorder.
Friday, June 26, 2015
Scientific News
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!